A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).

591 Background: TLS are organized lymphoid aggregates linked to improved response to immunotherapy in multiple cancers, including mRCC. Traditionally, TLS assessment relies on pathological staining of tumor sections. In this study, we evaluated the performance of TLS gene-expression signatures as an alternative diagnostic tool. Methods: Primary tumors from treatment-naïve patients with mRCC in the HCRN GU16-260 trial were analyzed using multiparametric immunofluorescence (IF), staining for CD3, CD20 (TLS), CD21 (mature TLS), and CD8. The counts and densities of total and mature TLS were calculated. Bulk RNA sequencing was performed on the same specimens, and 4 gene signature scores (Meylan, Cabrita, Coppola, and Ng) were estimated using gene set variation analysis (GSVA). Spearman's correlations between signature scores and TLS IF parameters, as well as the area under the receiver operator characteristic (AUROC) curve, were computed. Results: Our cohort included 78 patients with matched IF and RNA-seq data. All 4 TLS signatures demonstrated strong predictive performance for detecting the presence (vs. absence) of TLS by IF in each sample (AUROC 0.8 to 0.85). Quantitatively, the 4 TLS signature scores, measured as continuous variables, correlated with IF-based counts and densities of total TLS, and to a lesser extent, mature TLS (Table). In terms of comparative performance, Meylan’s signature showed the highest correlation with IF TLS features, while Ng’s was the least correlated (Table). Furthermore, Meylan’s signature achieved the best predictive ability to stratify high vs. low TLS (AUROC 0.83) and was more specifically correlated with TLS compared to CD8 density (Table). Conclusions: Expression-based signatures exhibit robust predictive ability for TLS detection and quantification, similar to previously established CD8 signatures, and represent valid surrogate tools to complement pathological diagnosis. Spearman’s correlations between IF parameters and TLS signatures. Parameter Meylan Cabrita Coppola Ng Total TLS count ρ=0.65, P= 1.1x10 -10 ρ=0.58, P= 2.9x10 -8 ρ=0.56, P= 7.1x10 -8 ρ=0.42, P= 1.4x10 -4 Mature TLS count ρ=0.51, P= 2.1x10 -6 ρ=0.41, P= 1.8x10 -4 ρ=0.34, P= 2.3x10 -3 ρ=0.39, P= 5.0x10 -4 Total TLS density ρ=0.63, P= 6.1x10 -10 ρ=0.58, P= 3.4x10 -8 ρ=0.55, P= 2.2x10 -7 ρ=0.42, P= 1.4x10 -4 Mature TLS density ρ=0.49, P= 5.1x10 -6 ρ=0.39, P= 3.5x10 -3 ρ=0.32, P= 4.3x10 -3 ρ=0.38, P= 6.8x10 -4 CD8 density ρ=0.42, P= 3.1x10 -4 ρ=0.62, P= 2.1x10 -8 ρ=0.67, P <2.2x10 -16 ρ=0.35, P= 2.9x10 -3

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-02-10
DOI
https://doi.org/10.1200/jco.2025.43.5_suppl.591
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).

David F. McDermott, Eddy Saad, Elizabeth R. Plimack, Sayed Matar et al.
2 links
Journal of Clinical Oncology
Ferroptosis and cancer prognosis
article

A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).

David F. McDermott, Eddy Saad, Elizabeth R. Plimack, Sayed Matar, Eliezer M. Van Allen, Naomi B. Haas, Toni K. Choueiri, Nourhan El Ahmar, David A. Braun, Jeffrey A. Sosman, Michael E. Hurwitz, Emre Yekedüz, Opeyemi A. Jegede, Razan Mohanna, Hans J. Hammers, Michael B. Atkins, Berkay Simsek
article en

Abstract

591 Background: TLS are organized lymphoid aggregates linked to improved response to immunotherapy in multiple cancers, including mRCC. Traditionally, TLS assessment relies on pathological staining of tumor sections. In this study, we evaluated the performance of TLS gene-expression signatures as an alternative diagnostic tool. Methods: Primary tumors from treatment-naïve patients with mRCC in the HCRN GU16-260 trial were analyzed using multiparametric immunofluorescence (IF), staining for CD3, CD20 (TLS), CD21 (mature TLS), and CD8. The counts and densities of total and mature TLS were calculated. Bulk RNA sequencing was performed on the same specimens, and 4 gene signature scores (Meylan, Cabrita, Coppola, and Ng) were estimated using gene set variation analysis (GSVA). Spearman's correlations between signature scores and TLS IF parameters, as well as the area under the receiver operator characteristic (AUROC) curve, were computed. Results: Our cohort included 78 patients with matched IF and RNA-seq data. All 4 TLS signatures demonstrated strong predictive performance for detecting the presence (vs. absence) of TLS by IF in each sample (AUROC 0.8 to 0.85). Quantitatively, the 4 TLS signature scores, measured as continuous variables, correlated with IF-based counts and densities of total TLS, and to a lesser extent, mature TLS (Table). In terms of comparative performance, Meylan’s signature showed the highest correlation with IF TLS features, while Ng’s was the least correlated (Table). Furthermore, Meylan’s signature achieved the best predictive ability to stratify high vs. low TLS (AUROC 0.83) and was more specifically correlated with TLS compared to CD8 density (Table). Conclusions: Expression-based signatures exhibit robust predictive ability for TLS detection and quantification, similar to previously established CD8 signatures, and represent valid surrogate tools to complement pathological diagnosis. Spearman’s correlations between IF parameters and TLS signatures. Parameter Meylan Cabrita Coppola Ng Total TLS count ρ=0.65, P= 1.1x10 -10 ρ=0.58, P= 2.9x10 -8 ρ=0.56, P= 7.1x10 -8 ρ=0.42, P= 1.4x10 -4 Mature TLS count ρ=0.51, P= 2.1x10 -6 ρ=0.41, P= 1.8x10 -4 ρ=0.34, P= 2.3x10 -3 ρ=0.39, P= 5.0x10 -4 Total TLS density ρ=0.63, P= 6.1x10 -10 ρ=0.58, P= 3.4x10 -8 ρ=0.55, P= 2.2x10 -7 ρ=0.42, P= 1.4x10 -4 Mature TLS density ρ=0.49, P= 5.1x10 -6 ρ=0.39, P= 3.5x10 -3 ρ=0.32, P= 4.3x10 -3 ρ=0.38, P= 6.8x10 -4 CD8 density ρ=0.42, P= 3.1x10 -4 ρ=0.62, P= 2.1x10 -8 ρ=0.67, P <2.2x10 -16 ρ=0.35, P= 2.9x10 -3

Journal of Clinical OncologyVol. 43(5_suppl)
Northwestern University (US), Brigham and Women's Hospital (US), Fox Chase Cancer Center (US), Beth Israel Deaconess Medical Center (US), Harvard University (US), Yale University (US), Dana-Farber Cancer Institute (US), Temple University Health System (US), Dana-Farber Brigham Cancer Center (US), Georgetown Lombardi Comprehensive Cancer Center, University of Pennsylvania (US), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 96%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.